Sept. 17, 2020 – The ATS Research Program is pleased to announce a new one-year grant supporting sarcoidosis research. The award by Mallinckrodt Pharmaceuticals provides $50,000 in funding.
Sarcoidosis is an inflammatory disease that affects the lungs, lymph glands, and other organs. The latest ATS guideline, published in March 2020, details the challenges associated with the illness. One of the authors of the guideline noted “the diagnosis of sarcoidosis is never fully certain.” Therefore, research support that will improve clinical outcomes is critical.
“The ATS Research Program/Mallinckrodt Pharmaceuticals Fellowship in Sarcoidosis is a prestigious international award designed to provide critical resources to promising early career investigators who aspire to improve the lives of our patients,” said Elliot D. Crouser, MD, co-author of the ATS clinical practice guideline on sarcoidosis. “This funding mechanism will foster scientific mentorship and hands-on research experience to establish the basic skills required for a productive academic career in the field of sarcoidosis research.”
“Mallinckrodt is honored to sponsor the ATS Research Program/Mallinckrodt Pharmaceuticals Fellowship in Sarcoidosis as part of our commitment to furthering understanding of this complex and difficult-to-diagnose disease,” said Steven Romano, MD, executive vice president and chief scientific officer at Mallinckrodt. “We look forward to the important work we expect will be produced by the early career investigators the fellowship supports.”
The application process will open Oct. 1, 2020.
Interested applicants may read more about this grant opportunity here.
